TITLE

I&I News Round-Up

PUB. DATE
October 2009
SOURCE
PharmaWatch: Monthly Review;Oct2009, Vol. 8 Issue 10, p15
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
The article offers news briefs related to pharmaceutical industries. Ranbaxy Laboratories Ltd. has been allowed by the Food and Drug Administration (FDA) to manufacture and market glycopyrrolate tablets USP 1mg and 2mg. An agreement to acquire Desonate and Neobenz micro from SkinMedica has been signed by Intendis, which is a part of Bayer Healthcare AG. Zithranol-RR, a prescription cream for psoriasis, has been launched by dermatology company Elorac.
ACCESSION #
44767507

 

Related Articles

  • FDA Update.  // Pharmaceutical Processing;Oct2008, Vol. 12 Issue 10, p50 

    The article reports updates related to the U.S. Food and Drug Administration (FDA). It states that the FDA has issued Warning Letters to Ranbaxy Laboratories Ltd., which identify the agency's concerns about deviations from the U.S. current Good Manufacturing Practice (cGMP) requirements at the...

  • Ranbaxy Laboratories Limited; Withdrawal of Approval of 27 Abbreviated New Drug Applications. Throckmorton, Douglas C. // Federal Register (National Archives & Records Service, Office of;8/22/2012, Vol. 77 Issue 163, p50702 

    The article offers information about a notice of withdrawal issued by the U.S. Food and Drug Administration (FDA) regarding withdrawal of approval of 27 abbreviated new drug applications (ANDAs) held by Ranbaxy Laboratories Ltd. It includes a list of drugs for which the approval has been...

  • Ranbaxy Laboratories Ltd.  // Chain Drug Review;9/28/2009, Vol. 31 Issue 16, p76 

    The article presents a corporate profile of research-based pharmaceutical company Ranbaxy Laboratories Ltd. in the U.S. The company has proven a record of offering high-quality pharmaceutical products on time to customers that are supported by its focus on supply chain management. Two-hundred...

  • Ranbaxy ANDAs to Be Withdrawn.  // BioWorld Today;8/22/2012, Vol. 23 Issue 163, p5 

    The article discusses the request of Ranbaxy Laboratories for the U.S. Food and Drug Administration (FDA) to withdraw the approval of its 27 abbreviated new drug applications (ANDA), which include dosages of cefaclor, cefprozil, and glimepiride.

  • U.S. Gives Nod to Ranbaxy for Lipitor.  // News India Times;12/09/2011, Vol. 42 Issue 49, p16 

    The article reports that the U.S. Food and Drug Administration (FDA) has given Ranbaxy Laboratories Ltd. an approval to launch the cholesterol-lowering drug Lipitor in the U.S.

  • Ranbaxy Laboratories obtains US FDA approval to market fenofibrate capsules.  // Express Pharma;10/01/2014, p1 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) for the Fenofibrate capsules of Indian pharmaceutical company Ranbaxy Laboratories Ltd. for primary hypercholesterolemia and mixed dyslipidemia, as well as severe hypertriglyceridemia.

  • Ranbaxy Receives Approval to Launch Generic Lipitor.  // India -- West;12/23/2011, Vol. 37 Issue 5, pA39 

    The article reports that generic drug maker Ranbaxy Laboratories Ltd. has received approval from the U.S. Food and Drug Administration to sell the generic version of cholesterol lowering blockbuster drug Lipitor.

  • Concerns over Ranbaxy drugs.  // Eastern Eye;11/14/2014, Issue 1277, p18 

    The article reports on the statement of the U.S. Food and Drug Administration (FDA) that it has withdrawn its tentative approval for esomeprazole magnesium and valganciclovir drugs from the drug company Ranbaxy Laboratories due to safety concerns about the pharmaceutical industry in India.

  • FDA/EMA ROUNDUP.  // MondayMorning;3/4/2013, Vol. 21 Issue 8, p1 

    The article offers news briefs related to pharmaceutical industries as of March 2013. The U.S. Food and Drug Administration (FDA) has approved Bayer Healthcare regarding its cancer pill for treating intestinal tract tumors. FDA has approved Osaka, Japan-based Shionogi & Co. Ltd. regarding the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics